The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Y-mAbs Therapeutics, Inc. announced positive results from the ...

Y-mAbs Therapeutics reported Q1 2025 revenues of $20.9 million, an 8% increase, with updates on clinical trials and business strategies. Y-mAbs Therapeutics, Inc. reported a net product revenue of $20 ...

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel ...

ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for ...

I-Mab Adr ( (IMAB)) has released its Q3 earnings. Here is a breakdown of the information I-Mab Adr presented to its investors. I-Mab is a U.S.-based global biotechnology company focused on developing ...

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab ...